Arch promoted by Ajit Kamath, Manoj Jain and Rajendra Kaimal is one of India's largest pure play intermediate players engaged in the manufacturing of pharmaceutical intermediates and APIs. It is a world leader in the Isoxazole Penicillins side chains market and the only supplier to offer intermediates for the entire basket of semi-synthetic Penicillins (SSPs) in the Isoxazole Penicillins range. The company’s non-compete strategy has made it a partner of choice for both custom synthesis and contract manufacturing opportunities. The company is currently focusing on expanding its Full Time Equivalence (FTE) business on the services side and Contract Manufacturing Operations for global companies on the manufacturing side. Its client list includes leading global players like, DSM, Codexis, Ribbon, Zambon, amongst other Indian pharma majors such as Ranbaxy, Dr. Reddy’s and Wockhardt.

Growing inorganically is one of Arch’s stated strategies. Arch has acquired and successfully integrated two companies namely Merven Drugs and Vitalife Laboratories.